Region-specific roles of the corticotropin-releasing factor-urocortin system in stress

Nature Reviews Neuroscience

Volumn 17, Issue 10, 2016, Pages 636-651

  Henckens, Marloes J A G ^a,b,c   Deussing, Jan M ^b   Chen, Alon ^a,b  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

^c RADBOUD UNIVERSITY   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID RECEPTOR; ANTIDEPRESSANT AGENT; CORTICOTROPIN; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYCLIC AMP DEPENDENT PROTEIN KINASE; ENDOCANNABINOID; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; UROCORTIN; CORTICOTROPIN RELEASING FACTOR RECEPTOR;

AMYGDALA; ANXIETY; BEHAVIOR; BRAIN REGION; BRAIN STEM; CELLS BY BODY ANATOMY; DEPRESSION; DOPAMINERGIC SYSTEM; DORSAL RAPHE NUCLEUS; GLUTAMATERGIC SYNAPSE; HIPPOCAMPUS; HOMEOSTASIS; HUMAN; HYPOTHALAMUS; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; LOCUS CERULEUS; MEDIAL PREFRONTAL CORTEX; MENTAL DISEASE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAPHE NUCLEUS; REVIEW; STRESS; SUBSTANTIA NIGRA; VENTRAL TEGMENTUM; ANIMAL; BIOLOGICAL MODEL; MENTAL STRESS; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANXIETY; CORTICOTROPIN-RELEASING HORMONE; DEPRESSION; HUMANS; MODELS, NEUROLOGICAL; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; STRESS, PSYCHOLOGICAL; UROCORTINS;

EID: 84984825577     PISSN: 1471003X     EISSN: 14710048     Source Type: Journal    
DOI: 10.1038/nrn.2016.94     Document Type: Review

References (228)

1. Vale, W., Spiess, J., Rivier, C. & Rivier, J. Characterization of a 41-residue ovine hypothalamic peptide that stimulates secretion of corticotropin and beta-endorphin. Science 213, 1394-1397 (1981).
2. Dunn, A. J. & Berridge, C. W. Is corticotropin-releasing factor a mediator of stress responses? Ann. NY Acad. Sci. 579, 183-191 (1990).
3. Bale, T. L. & Vale, W. W. CRF and CRF receptors: role in stress responsivity and other behaviors. Annu. Rev. Pharmacol. Toxicol. 44, 525-557 (2004).
4. Valentino, R. J., Foote, S. L. & Page, M. E. The locus coeruleus as a site for integrating corticotropin-releasing factor and noradrenergic mediation of stress responses. Ann. NY Acad. Sci. 697, 173-188 (1993).
5. Brown, M. R. et al. Corticotropin-releasing factor: actions on the sympathetic nervous system and metabolism. Endocrinology 111, 928-931 (1982).
6. Reul, J. M. & Holsboer, F. Corticotropin-releasing factor receptors 1 and 2 in anxiety and depression. Curr. Opin. Pharmacol. 2, 23-33 (2002).
7. 2, receptors mediate anxiogenic-like behavior. Regul. Pept. 71, 15-21 (1997).
8. van Gaalen, M. M., Stenzel-Poore, M. P., Holsboer, F. & Steckler, T. Effects of transgenic overproduction of CRH on anxiety-like behaviour. Eur. J. Neurosci. 15, 2007-2015 (2002).
9. Skutella, T. et al. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide induces anxiolytic effects in rat. Neuroreport 5, 2181-2185 (1994).
10. Skutella, T. et al. Corticotropin-releasing hormone (CRH) antisense oligodeoxynucleotide treatment attenuates social defeat-induced anxiety in rats. Cell. Mol. Neurobiol. 14, 579-588 (1994).
11. Nemeroff, C. B. et al. Elevated concentrations of CSF corticotropin-releasing factor-like immunoreactivity in depressed patients. Science 226, 1342-1344 (1984).
12. Bremner, J. D. et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am. J. Psychiatry 154, 624-629 (1997).
13. De Bellis, M. D. et al. Association of fluoxetine treatment with reductions in CSF concentrations of corticotropin-releasing hormone and arginine vasopressin in patients with major depression. Am. J. Psychiatry 150, 656-657 (1993).
14. Heuser, I. et al. Cerebrospinal fluid concentrations of corticotropin-releasing hormone, vasopressin, and somatostatin in depressed patients and healthy controls: response to amitriptyline treatment. Depress. Anxiety 8, 71-79 (1998).
15. Zorrilla, E. P., Valdez, G. R., Nozulak, J., Koob, G. F. & Markou, A. Effects of antalarmin, a CRF type 1 receptor antagonist, on anxiety-like behavior and motor activation in the rat. Brain Res. 952, 188-199 (2002).
16. Smith, G. W. et al. Corticotropin releasing factor receptor 1-deficient mice display decreased anxiety, impaired stress response, and aberrant neuroendocrine development. Neuron 20, 1093-1102 (1998).
17. Timpl, P. et al. Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1. Nat. Genet. 19, 162-166 (1998).
18. Muller, M. B. et al. Limbic corticotropin-releasing hormone receptor 1 mediates anxiety-related behavior and hormonal adaptation to stress. Nat. Neurosci. 6, 1100-1107 (2003).
19. Bale, T. L. et al. Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat. Genet. 24, 410-414 (2000).
20. Coste, S. C. et al. Abnormal adaptations to stress and impaired cardiovascular function in mice lacking corticotropin-releasing hormone receptor 2. Nat. Genet. 24, 403-409 (2000).
21. Kishimoto, T. et al. Deletion of Crhr2 reveals an anxiolytic role for corticotropin-releasing hormone receptor 2. Nat. Genet. 24, 415-419 (2000).
22. Issler, O. et al. Increased anxiety in corticotropin-releasing factor type 2 receptor-null mice requires recent acute stress exposure and is associated with dysregulated serotonergic activity in limbic brain areas. Biol. Mood Anxiety Disord. 4, 1 (2014).
23. Neufeld-Cohen, A. et al. A triple urocortin knockout mouse model reveals an essential role for urocortins in stress recovery. Proc. Natl Acad. Sci. USA 107, 19020-19025 (2010).
24. Maier, S. F. & Watkins, L. R. Stressor controllability and learned helplessness: the roles of the dorsal raphe nucleus, serotonin, and corticotropin-releasing factor. Neurosci. Biobehav. Rev. 29, 829-841 (2005).
25. Valentino, R. J. & Commons, K. G. Peptides that fine-tune the serotonin system. Neuropeptides 39, 1-8 (2005).
26. Bale, T. L. & Vale, W. W. Increased depression-like behaviors in corticotropin-releasing factor receptor-2-deficient mice: sexually dichotomous responses. J. Neurosci. 23, 5295-5301 (2003).
27. Janssen, D. & Kozicz, T. Is it really a matter of simple dualism? Corticotropin-releasing factor receptors in body and mental health. Front. Endocrinol. (Lausanne) 4, 28 (2013).
28. Radulovic, J., Ruhmann, A., Liepold, T. & Spiess, J. Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J. Neurosci. 19, 5016-5025 (1999).
29. 2 receptors. PLoS ONE 8, e63942 (2013).
30. Justice, N. J., Yuan, Z. F., Sawchenko, P. E. & Vale, W. Type 1 corticotropin-releasing factor receptor expression reported in BAC transgenic mice: implications for reconciling ligand-receptor mismatch in the central corticotropin-releasing factor system. J. Comp. Neurol. 511, 479-496 (2008).
31. Kuhne, C. et al. Visualizing corticotropin-releasing hormone receptor type 1 expression and neuronal connectivities in the mouse using a novel multifunctional allele. J. Comp. Neurol. 520, 3150-3180 (2012).
32. 1 receptor mRNA expression. J. Neurosci. 15, 6340-6350 (1995).
33. Van Pett, K. et al. Distribution of mRNAs encoding CRF receptors in brain and pituitary of rat and mouse. J. Comp. Neurol. 428, 191-212 (2000).
34. Reyes, B. A., Valentino, R. J. & Van Bockstaele, E. J. Stress-induced intracellular trafficking of corticotropin-releasing factor receptors in rat locus coeruleus neurons. Endocrinology 149, 122-130 (2008).
35. Reyes, B. A., Bangasser, D. A., Valentino, R. J. & Van Bockstaele, E. J. Using high resolution imaging to determine trafficking of corticotropin-releasing factor receptors in noradrenergic neurons of the rat locus coeruleus. Life Sci. 112, 2-9 (2014).
36. Davis, M., Walker, D. L., Miles, L. & Grillon, C. Phasic versus sustained fear in rats and humans: role of the extended amygdala in fear versus anxiety. Neuropsychopharmacology 35, 105-135 (2010).
37. Roozendaal, B., McEwen, B. S. & Chattarji, S. Stress, memory and the amygdala. Nat. Rev. Neurosci. 10, 423-433 (2009).
38. Rostkowski, A. B., Leitermann, R. J. & Urban, J. H. Differential activation of neuronal cell types in the basolateral amygdala by corticotropin releasing factor. Neuropeptides 47, 273-280 (2013).
39. Rainnie, D. G., Fernhout, B. J. & Shinnick-Gallagher, P. Differential actions of corticotropin releasing factor on basolateral and central amygdaloid neurones, in vitro. J. Pharmacol. Exp. Ther. 263, 846-858 (1992).
40. Refojo, D. et al. Glutamatergic and dopaminergic neurons mediate anxiogenic and anxiolytic effects of CRHR1. Science 333, 1903-1907 (2011).
41. 1 receptor. Eur. J. Pharmacol. 509, 145-153 (2005).
42. Sajdyk, T. J., Schober, D. A., Gehlert, D. R. & Shekhar, A. Role of corticotropin-releasing factor and urocortin within the basolateral amygdala of rats in anxiety and panic responses. Behav. Brain Res. 100, 207-215 (1999).
43. Spiga, F., Lightman, S. L., Shekhar, A. & Lowry, C. A. Injections of urocortin 1 into the basolateral amygdala induce anxiety-like behavior and c-Fos expression in brainstem serotonergic neurons. Neuroscience 138, 1265-1276 (2006).
44. Bijlsma, E. Y., van Leeuwen, M. L., Westphal, K. G., Olivier, B. & Groenink, L. Local repeated corticotropin-releasing factor infusion exacerbates anxiety- and fear-related behavior: differential involvement of the basolateral amygdala and medial prefrontal cortex. Neuroscience 173, 82-92 (2011).
45. Abiri, D. et al. Fear extinction learning can be impaired or enhanced by modulation of the CRF system in the basolateral nucleus of the amygdala. Behav. Brain Res. 271, 234-239 (2014).
46. Roozendaal, B., Brunson, K. L., Holloway, B. L., McGaugh, J. L. & Baram, T. Z. Involvement of stress-released corticotropin-releasing hormone in the basolateral amygdala in regulating memory consolidation. Proc. Natl Acad. Sci. USA 99, 13908-13913 (2002).
47. Roozendaal, B., Schelling, G. & McGaugh, J. L. Corticotropin-releasing factor in the basolateral amygdala enhances memory consolidation via an interaction with the β-adrenoceptor-cAMP pathway: dependence on glucocorticoid receptor activation. J. Neurosci. 28, 6642-6651 (2008).
48. Hubbard, D. T., Nakashima, B. R., Lee, I. & Takahashi, L. K. Activation of basolateral amygdala corticotropin-releasing factor 1 receptors modulates the consolidation of contextual fear. Neuroscience 150, 818-828 (2007).
49. Sztainberg, Y., Kuperman, Y., Tsoory, M., Lebow, M. & Chen, A. The anxiolytic effect of environmental enrichment is mediated via amygdalar CRF receptor type 1. Mol. Psychiatry 15, 905-917 (2010).
50. Gray, J. M. et al. Corticotropin-releasing hormone drives anandamide hydrolysis in the amygdala to promote anxiety. J. Neurosci. 35, 3879-3892 (2015).
51. Veening, J. G., Swanson, L. W. & Sawchenko, P. E. The organization of projections from the central nucleus of the amygdala to brainstem sites involved in central autonomic regulation: a combined retrograde transport-immunohistochemical study. Brain Res. 303, 337-357 (1984).
52. LeDoux, J. E., Iwata, J., Cicchetti, P. & Reis, D. J. Different projections of the central amygdaloid nucleus mediate autonomic and behavioral correlates of conditioned fear. J. Neurosci. 8, 2517-2529 (1988).
53. Silberman, Y. & Winder, D. G. Ethanol and corticotropin releasing factor receptor modulation of central amygdala neurocircuitry: an update and future directions. Alcohol 49, 179-184 (2015).
54. Yu, B. & Shinnick-Gallagher, P. Corticotropin-releasing factor increases dihydropyridine- and neurotoxin-resistant calcium currents in neurons of the central amygdala. J. Pharmacol. Exp. Ther. 284, 170-179 (1998).
55. Silberman, Y. & Winder, D. G. Corticotropin releasing factor and catecholamines enhance glutamatergic neurotransmission in the lateral subdivision of the central amygdala. Neuropharmacology 70, 316-323 (2013).
56. Ji, G. & Neugebauer, V. Pro- and anti-nociceptive effects of corticotropin-releasing factor (CRF) in central amygdala neurons are mediated through different receptors. J. Neurophysiol. 99, 1201-1212 (2008).
57. Fu, Y. & Neugebauer, V. Differential mechanisms of CRF1 and CRF2 receptor functions in the amygdala in pain-related synaptic facilitation and behavior. J. Neurosci. 28, 3861-3876 (2008).
58. Liu, J. et al. Corticotropin-releasing factor and urocortin I modulate excitatory glutamatergic synaptic transmission. J. Neurosci. 24, 4020-4029 (2004).
59. Nie, Z. et al. Ethanol augments GABAergic transmission in the central amygdala via CRF1 receptors. Science 303, 1512-1514 (2004).
60. 1 receptors mediate the ethanol enhancement of GABAergic transmission in the mouse central amygdala. ScientificWorldJournal 9, 68-85 (2009).
61. Gilpin, N. W., Herman, M. A. & Roberto, M. The central amygdala as an integrative hub for anxiety and alcohol use disorders. Biol. Psychiatry 77, 859-869 (2015).
62. Herman, M. A. et al. Glutamatergic transmission in the central nucleus of the amygdala is selectively altered in Marchigian Sardinian alcohol-preferring rats: alcohol and CRF effects. Neuropharmacology 102, 21-31 (2016).
63. Henry, B., Vale, W. & Markou, A. The effect of lateral septum corticotropin-releasing factor receptor 2 activation on anxiety is modulated by stress. J. Neurosci. 26, 9142-9152 (2006).
64. 1 receptor antisense oligodeoxynucleotide into the central nucleus of the amygdala reduced anxiety-related behavior in socially defeated rats. Regul. Pept. 59, 229-239 (1995).
65. Ji, G., Fu, Y., Adwanikar, H. & Neugebauer, V. Non pain-related CRF1 activation in the amygdala facilitates synaptic transmission and pain responses. Mol. Pain 9, 2 (2013).
66. Ji, G., Fu, Y., Ruppert, K. A. & Neugebauer, V. Pain-related anxiety-like behavior requires CRF1 receptors in the amygdala. Mol. Pain 3, 13 (2007).
67. Haramati, S. et al. MicroRNA as repressors of stress-induced anxiety: the case of amygdalar miR 34. J. Neurosci. 31, 14191-14203 (2011).
68. Matys, T. et al. Tissue plasminogen activator promotes the effects of corticotropin-releasing factor on the amygdala and anxiety-like behavior. Proc. Natl Acad. Sci. USA 101, 16345-16350 (2004).
69. Pawlak, R., Magarinos, A. M., Melchor, J., McEwen, B. & Strickland, S. Tissue plasminogen activator in the amygdala is critical for stress-induced anxiety-like behavior. Nat. Neurosci. 6, 168-174 (2003).
70. Davis, M. Are different parts of the extended amygdala involved in fear versus anxiety? Biol. Psychiatry 44, 1239-1247 (1998).
71. Kash, T. L., Nobis, W. P., Matthews, R. T. & Winder, D. G. Dopamine enhances fast excitatory synaptic transmission in the extended amygdala by a CRF-R1-dependent process. J. Neurosci. 28, 13856-13865 (2008).
72. Silberman, Y., Matthews, R. T. & Winder, D. G. A corticotropin releasing factor pathway for ethanol regulation of the ventral tegmental area in the bed nucleus of the stria terminalis. J. Neurosci. 33, 950-960 (2013).
73. Sahuque, L. L. et al. Anxiogenic and aversive effects of corticotropin-releasing factor (CRF) in the bed nucleus of the stria terminalis in the rat: role of CRF receptor subtypes. Psychopharmacol. (Berl.) 186, 122-132 (2006).
74. Nobis, W. P., Kash, T. L., Silberman, Y. & Winder, D. G. β-Adrenergic receptors enhance excitatory transmission in the bed nucleus of the stria terminalis through a corticotrophin-releasing factor receptor-dependent and cocaine-regulated mechanism. Biol. Psychiatry 69, 1083-1090 (2011).
75. Tran, L., Schulkin, J. & Greenwood-Van Meerveld, B. Importance of CRF receptor-mediated mechanisms of the bed nucleus of the stria terminalis in the processing of anxiety and pain. Neuropsychopharmacology 39, 2633-2645 (2014).
76. Huang, M. M. et al. Corticotropin-releasing factor (CRF) sensitization of ethanol withdrawal-induced anxiety-like behavior is brain site specific and mediated by CRF-1 receptors: relation to stress-induced sensitization. J. Pharmacol. Exp. Ther. 332, 298-307 (2010).
77. Maras, P. M. & Baram, T. Z. Sculpting the hippocampus from within: stress, spines, and CRH. Trends Neurosci. 35, 315-324 (2012).
78. Chen, Y., Andres, A. L., Frotscher, M. & Baram, T. Z. Tuning synaptic transmission in the hippocampus by stress: the CRH system. Front. Cell. Neurosci. 6, 13 (2012).
79. Aldenhoff, J. B., Gruol, D. L., Rivier, J., Vale, W. & Siggins, G. R. Corticotropin releasing factor decreases postburst hyperpolarizations and excites hippocampal neurons. Science 221, 875-877 (1983).
80. Blank, T., Nijholt, I., Eckart, K. & Spiess, J. Priming of long-term potentiation in mouse hippocampus by corticotropin-releasing factor and acute stress: implications for hippocampus-dependent learning. J. Neurosci. 22, 3788-3794 (2002).
81. Hung, H. C., Chou, C. K., Chiu, T. H. & Lee, E. H. CRF increases protein phosphorylation and enhances retention performance in rats. Neuroreport 3, 181-184 (1992).
82. Ma, Y. L., Chen, K. Y., Wei, C. L. & Lee, E. H. Corticotropin-releasing factor enhances brain-derived neurotrophic factor gene expression to facilitate memory retention in rats. Chin. J. Physiol. 42, 73-81 (1999).
83. Pentkowski, N. S. et al. Effects of acidic-astressin and ovine-CRF microinfusions into the ventral hippocampus on defensive behaviors in rats. Horm. Behav. 56, 35-43 (2009).
84. Contarino, A. et al. Reduced anxiety-like and cognitive performance in mice lacking the corticotropin-releasing factor receptor 1. Brain Res. 835, 1-9 (1999).
85. Croiset, G., Nijsen, M. J. & Kamphuis, P. J. Role of corticotropin-releasing factor, vasopressin and the autonomic nervous system in learning and memory. Eur. J. Pharmacol. 405, 225-234 (2000).
86. Stern, C. M., Meitzen, J. & Mermelstein, P. G. Corticotropin-releasing factor and urocortin I activate CREB through functionally selective Gβγ signaling in hippocampal pyramidal neurons. Eur. J. Neurosci. 34, 671-681 (2011).
87. Sheng, H. et al. Corticotropin-releasing hormone stimulates SGK-1 kinase expression in cultured hippocampal neurons via CRH R1. Am. J. Physiol. Endocrinol. Metab. 295, E938-E946 (2008).
88. Bonci, A. & Borgland, S. Role of orexin/hypocretin and CRF in the formation of drug-dependent synaptic plasticity in the mesolimbic system. Neuropharmacology 56, 107-111 (2009).
89. Wise, R. A. & Morales, M. A ventral tegmental CRF-glutamate-dopamine interaction in addiction. Brain Res. 1314, 38-43 (2010).
90. Zorrilla, E. P., Logrip, M. L. & Koob, G. F. Corticotropin releasing factor: a key role in the neurobiology of addiction. Front. Neuroendocrinol. 35, 234-244 (2014).
91. Korotkova, T. M., Brown, R. E., Sergeeva, O. A., Ponomarenko, A. A. & Haas, H. L. Effects of arousal- and feeding-related neuropeptides on dopaminergic and GABAergic neurons in the ventral tegmental area of the rat. Eur. J. Neurosci. 23, 2677-2685 (2006).
92. Williams, C. L., Buchta, W. C. & Riegel, A. C. CRF R2 and the heterosynaptic regulation of VTA glutamate during reinstatement of cocaine seeking. J. Neurosci. 34, 10402-10414 (2014).
93. Wanat, M. J., Hopf, F. W., Stuber, G. D., Phillips, P. E. & Bonci, A. Corticotropin-releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein kinase C-dependent enhancement of Ih. J. Physiol. 586, 2157-2170 (2008).
94. Kalivas, P. W., Duffy, P. & Latimer, L. G. Neurochemical and behavioral effects of corticotropin-releasing factor in the ventral tegmental area of the rat. J. Pharmacol. Exp. Ther. 242, 757-763 (1987).
95. Wang, B. et al. Cocaine experience establishes control of midbrain glutamate and dopamine by corticotropin-releasing factor: a role in stress-induced relapse to drug seeking. J. Neurosci. 25, 5389-5396 (2005).
96. Sparta, D. R. et al. Binge ethanol-drinking potentiates corticotropin releasing factor R1 receptor activity in the ventral tegmental area. Alcohol Clin. Exp. Res. 37, 1680-1687 (2013).
97. Hahn, J., Hopf, F. W. & Bonci, A. Chronic cocaine enhances corticotropin-releasing factor-dependent potentiation of excitatory transmission in ventral tegmental area dopamine neurons. J. Neurosci. 29, 6535-6544 (2009).
98. 2 receptor and CRF-binding protein in the ventral tegmental area of the rat. Psychopharmacol. (Berl.) 193, 283-294 (2007).
99. Blacktop, J. M. et al. Augmented cocaine seeking in response to stress or CRF delivered into the ventral tegmental area following long-access self-administration is mediated by CRF receptor type 1 but not CRF receptor type 2. J. Neurosci. 31, 11396-11403 (2011).
100. Grieder, T. E. et al. VTA CRF neurons mediate the aversive effects of nicotine withdrawal and promote intake escalation. Nat. Neurosci. 17, 1751-1758 (2014).
101. Boyson, C. O. et al. Social stress and CRF-dopamine interactions in the VTA: role in long-term escalation of cocaine self-administration. J. Neurosci. 34, 6659-6667 (2014).
102. 1 receptors in the rat and mouse VTA and DRN. Psychopharmacol. (Berl.) 225, 313-327 (2013).
103. Chen, N. A. et al. Knockdown of CRF1 receptors in the ventral tegmental area attenuates cue- and acute food deprivation stress-induced cocaine seeking in mice. J. Neurosci. 34, 11560-11570 (2014).
104. Wanat, M. J., Bonci, A. & Phillips, P. E. CRF acts in the midbrain to attenuate accumbens dopamine release to rewards but not their predictors. Nat. Neurosci. 16, 383-385 (2013).
105. 2+ channels. Neurosci. Lett. 465, 31-35 (2009).
106. Foote, S. L., Bloom, F. E. & Aston-Jones, G. Nucleus locus ceruleus: new evidence of anatomical and physiological specificity. Physiol. Rev. 63, 844-914 (1983).
107. Zitnik, G. A. Control of arousal through neuropeptide afferents of the locus coeruleus. Brain Res. 1641, 338-350 (2015).
108. Aston-Jones, G. & Bloom, F. E. Activity of norepinephrine-containing locus coeruleus neurons in behaving rats anticipates fluctuations in the sleep-waking cycle. J. Neurosci. 1, 876-886 (1981).
109. Aston-Jones, G. & Bloom, F. E. Norepinephrine-containing locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J. Neurosci. 1, 887-900 (1981).
110. Rassnick, S., Hoffman, G. E., Rabin, B. S. & Sved, A. F. Injection of corticotropin-releasing hormone into the locus coeruleus or foot shock increases neuronal Fos expression. Neuroscience 85, 259-268 (1998).
111. Curtis, A. L., Lechner, S. M., Pavcovich, L. A. & Valentino, R. J. Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J. Pharmacol. Exp. Ther. 281, 163-172 (1997).
112. Aston-Jones, G. & Cohen, J. D. An integrative theory of locus coeruleus-norepinephrine function: adaptive gain and optimal performance. Annu. Rev. Neurosci. 28, 403-450 (2005).
113. Valentino, R. J. & Van Bockstaele, E. Convergent regulation of locus coeruleus activity as an adaptive response to stress. Eur. J. Pharmacol. 583, 194-203 (2008).
114. Devilbiss, D. M., Waterhouse, B. D., Berridge, C. W. & Valentino, R. Corticotropin-releasing factor acting at the locus coeruleus disrupts thalamic and cortical sensory-evoked responses. Neuropsychopharmacology 37, 2020-2030 (2012).
115. Snyder, K., Wang, W. W., Han, R., McFadden, K. & Valentino, R. J. Corticotropin-releasing factor in the norepinephrine nucleus, locus coeruleus, facilitates behavioral flexibility. Neuropsychopharmacology 37, 520-530 (2012).
116. Reyes, B. A., Fox, K., Valentino, R. J. & Van Bockstaele, E. J. Agonist-induced internalization of corticotropin-releasing factor receptors in noradrenergic neurons of the rat locus coeruleus. Eur. J. Neurosci. 23, 2991-2998 (2006).
117. Jedema, H. P. & Grace, A. A. Corticotropin-releasing hormone directly activates noradrenergic neurons of the locus ceruleus recorded in vitro. J. Neurosci. 24, 9703-9713 (2004).
118. 1 receptor antagonist, DMP695, abolishes activation of locus coeruleus noradrenergic neurones by CRF in anesthetized rats. Eur. J. Pharmacol. 464, 127-133 (2003).
119. McCall, J. G. et al. CRH engagement of the locus coeruleus noradrenergic system mediates stress-induced anxiety. Neuron 87, 605-620 (2015).
120. Chaijale, N. N. et al. Social stress engages opioid regulation of locus coeruleus norepinephrine neurons and induces a state of cellular and physical opiate dependence. Neuropsychopharmacology 38, 1833-1843 (2013).
121. 1 receptor levels in learned helpless and non-helpless rats: a potential link to stress resilience. Behav. Brain Res. 221, 25-33 (2011).
122. Curtis, A. L., Pavcovich, L. A., Grigoriadis, D. E. & Valentino, R. J. Previous stress alters corticotropin-releasing factor neurotransmission in the locus coeruleus. Neuroscience 65, 541-550 (1995).
123. Curtis, A. L., Pavcovich, L. A. & Valentino, R. J. Long-term regulation of locus ceruleus sensitivity to corticotropin-releasing factor by swim stress. J. Pharmacol. Exp. Ther. 289, 1211-1219 (1999).
124. Bangasser, D. A. et al. Sex differences in corticotropin-releasing factor receptor signaling and trafficking: potential role in female vulnerability to stress-related psychopathology. Mol. Psychiatry 877, 896-904 (2010).
125. Retson, T. A., Reyes, B. A. & Van Bockstaele, E. J. Chronic alcohol exposure differentially affects activation of female locus coeruleus neurons and the subcellular distribution of corticotropin releasing factor receptors. Prog. Neuropsychopharmacol. Biol. Psychiatry 56, 66-74 (2015).
126. Roche, M., Commons, K. G., Peoples, A. & Valentino, R. J. Circuitry underlying regulation of the serotonergic system by swim stress. J. Neurosci. 23, 970-977 (2003).
127. Waselus, M., Nazzaro, C., Valentino, R. J. & Van Bockstaele, E. J. Stress-induced redistribution of corticotropin-releasing factor receptor subtypes in the dorsal raphe nucleus. Biol. Psychiatry 66, 76-83 (2009).
128. Kirby, L. G., Rice, K. C. & Valentino, R. J. Effects of corticotropin-releasing factor on neuronal activity in the serotonergic dorsal raphe nucleus. Neuropsychopharmacology 22, 148-162 (2000).
129. Lukkes, J. L., Forster, G. L., Renner, K. J. & Summers, C. H. Corticotropin-releasing factor 1 and 2 receptors in the dorsal raphe differentially affect serotonin release in the nucleus accumbens. Eur. J. Pharmacol. 578, 185-193 (2008).
130. Price, M. L., Curtis, A. L., Kirby, L. G., Valentino, R. J. & Lucki, I. Effects of corticotropin-releasing factor on brain serotonergic activity. Neuropsychopharmacology 18, 492-502 (1998).
131. Price, M. L. & Lucki, I. Regulation of serotonin release in the lateral septum and striatum by corticotropin-releasing factor. J. Neurosci. 21, 2833-2841 (2001).
132. 2A receptor activation in the dorsolateral septum facilitates inhibitory avoidance in the elevated T-maze. Behav. Brain Res. 226, 50-55 (2012).
133. Fox, J. H. & Lowry, C. A. Corticotropin-releasing factor-related peptides, serotonergic systems, and emotional behavior. Front. Neurosci. 7, 169 (2013).
134. Bowers, L. K., Swisher, C. B. & Behbehani, M. M. Membrane and synaptic effects of corticotropin-releasing factor on periaqueductal gray neurons of the rat. Brain Res. 981, 52-57 (2003).
135. Martins, A. P., Marras, R. A. & Guimaraes, F. S. Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray. Depress. Anxiety 12, 99-101 (2000).
136. Sergio Tde, O., Spiacci, A. Jr & Zangrossi, H. Jr. Effects of dorsal periaqueductal gray CRF1- and CRF2 receptor stimulation in animal models of panic. Psychoneuroendocrinology 49, 321-330 (2014).
137. Litvin, Y., Pentkowski, N. S., Blanchard, D. C. & Blanchard, R. J. CRF type 1 receptors in the dorsal periaqueductal gray modulate anxiety-induced defensive behaviors. Horm. Behav. 52, 244-251 (2007).
138. Miguel, T. T. & Nunes-de-Souza, R. L. Anxiogenic and antinociceptive effects induced by corticotropin-releasing factor (CRF) injections into the periaqueductal gray are modulated by CRF1 receptor in mice. Horm. Behav. 60, 292-300 (2011).
139. Ji, G. & Neugebauer, V. Differential effects of CRF1 and CRF2 receptor antagonists on pain-related sensitization of neurons in the central nucleus of the amygdala. J. Neurophysiol. 97, 3893-3904 (2007).
140. Elharrar, E. et al. Overexpression of corticotropin-releasing factor receptor type 2 in the bed nucleus of stria terminalis improves posttraumatic stress disorder-like symptoms in a model of incubation of fear. Biol. Psychiatry 74, 827-836 (2013).
141. Lebow, M. et al. Susceptibility to PTSD-like behavior is mediated by corticotropin-releasing factor receptor type 2 levels in the bed nucleus of the stria terminalis. J. Neurosci. 32, 6906-6916 (2012).
142. Hammack, S. E., Mania, I. & Rainnie, D. G. Differential expression of intrinsic membrane currents in defined cell types of the anterolateral bed nucleus of the stria terminalis. J. Neurophysiol. 98, 638-656 (2007).
143. Lebow, M. A. & Chen, A. Overshadowed by the amygdala: the bed nucleus of the stria terminalis emerges as key to psychiatric disorders. Mol. Psychiatry 21, 450-463 (2016).
144. Myers, B., Mark Dolgas, C., Kasckow, J., Cullinan, W. E. & Herman, J. P. Central stress-integrative circuits: forebrain glutamatergic and GABAergic projections to the dorsomedial hypothalamus, medial preoptic area, and bed nucleus of the stria terminalis. Brain Struct. Funct. 219, 1287-1303 (2014).
145. Anthony, T. E. et al. Control of stress-induced persistent anxiety by an extra-amygdala septohypothalamic circuit. Cell 156, 522-536 (2014).
146. Gallagher, J. P., Orozco-Cabal, L. F., Liu, J. & Shinnick-Gallagher, P. Synaptic physiology of central CRH system. Eur. J. Pharmacol. 583, 215-225 (2008).
147. 2 receptor-mediated depression to facilitation of glutamatergic transmission in the lateral septum. J. Neurosci. 25, 577-583 (2005).
148. 1 receptors in amygdala. J. Neurosci. 22, 2926-2935 (2002).
149. Ho, S. P. et al. Attenuation of fear conditioning by antisense inhibition of brain corticotropin releasing factor-2 receptor. Brain Res. Mol. Brain Res. 89, 29-40 (2001).
150. Todorovic, C. et al. Differential activation of CRF receptor subtypes removes stress-induced memory deficit and anxiety. Eur. J. Neurosci. 25, 3385-3397 (2007).
151. Ungless, M. A. et al. Corticotropin-releasing factor requires CRF binding protein to potentiate NMDA receptors via CRF receptor 2 in dopamine neurons. Neuron 39, 401-407 (2003).
152. 1b adrenergic, CRF-R1, and CRF-R2 receptor mRNA in serotonergic, γ-aminobutyric acidergic, and catecholaminergic cells of the rat dorsal raphe nucleus. J. Comp. Neurol. 474, 364-378 (2004).
153. Pernar, L., Curtis, A. L., Vale, W. W., Rivier, J. E. & Valentino, R. J. Selective activation of corticotropin-releasing factor-2 receptors on neurochemically identified neurons in the rat dorsal raphe nucleus reveals dual actions. J. Neurosci. 24, 1305-1311 (2004).
154. Lowry, C. A., Rodda, J. E., Lightman, S. L. & Ingram, C. D. Corticotropin-releasing factor increases in vitro firing rates of serotonergic neurons in the rat dorsal raphe nucleus: evidence for activation of a topographically organized mesolimbocortical serotonergic system. J. Neurosci. 20, 7728-7736 (2000).
155. 2C receptors in the basolateral amygdala and dorsal striatum are a novel target for the anxiolytic and antidepressant effects of exercise. PLoS ONE 7, e46118 (2012).
156. Campbell, B. M. & Merchant, K. M. Serotonin 2C receptors within the basolateral amygdala induce acute fear-like responses in an open-field environment. Brain Res. 993, 1-9 (2003).
157. Forster, G. L. et al. Corticotropin-releasing factor in the dorsal raphe nucleus increases medial prefrontal cortical serotonin via type 2 receptors and median raphe nucleus activity. Eur. J. Neurosci. 28, 299-310 (2008).
158. Hammack, S. E. et al. The role of corticotropin-releasing hormone in the dorsal raphe nucleus in mediating the behavioral consequences of uncontrollable stress. J. Neurosci. 22, 1020-1026 (2002).
159. Hammack, S. E. et al. Corticotropin releasing hormone type 2 receptors in the dorsal raphe nucleus mediate the behavioral consequences of uncontrollable stress. J. Neurosci. 23, 1019-1025 (2003).
160. Orozco-Cabal, L., Pollandt, S., Liu, J., Shinnick-Gallagher, P. & Gallagher, J. P. Regulation of synaptic transmission by CRF receptors. Rev. Neurosci. 17, 279-307 (2006).
161. Dabrowska, J., Hazra, R., Guo, J. D., Dewitt, S. & Rainnie, D. G. Central CRF neurons are not created equal: phenotypic differences in CRF-containing neurons of the rat paraventricular hypothalamus and the bed nucleus of the stria terminalis. Front. Neurosci. 7, 156 (2013).
162. Pomrenze, M. B. et al. A transgenic rat for investigating the anatomy and function of corticotrophin releasing factor circuits. Front. Neurosci. 9, 487 (2015).
163. Partridge, J. G. et al. Stress increases GABAergic neurotransmission in CRF neurons of the central amygdala and bed nucleus stria terminalis. Neuropharmacology 107, 239-250 (2016).
164. Chen, Y. et al. Hippocampal corticotropin releasing hormone: pre- and postsynaptic location and release by stress. Neuroscience 126, 533-540 (2004).
165. Crawley, J. N., Olschowka, J. A., Diz, D. I. & Jacobowitz, D. M. Behavioral investigation of the coexistence of substance P, corticotropin releasing factor, and acetylcholinesterase in lateral dorsal tegmental neurons projecting to the medial frontal cortex of the rat. Peptides 6, 891-901 (1985).
166. Zhao-Shea, R. et al. Increased CRF signalling in a ventral tegmental area-interpeduncular nucleus-medial habenula circuit induces anxiety during nicotine withdrawal. Nat. Commun. 6, 6770 (2015).
167. Magalhaes, A. C. et al. CRF receptor 1 regulates anxiety behavior via sensitization of 5 HT2 receptor signaling. Nat. Neurosci. 13, 622-629 (2010).
168. Holsboer, F. The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J. Psychiatr. Res. 33, 181-214 (1999).
169. Chen, P., Vaughan, J., Donaldson, C., Vale, W. & Li, C. Injection of urocortin 3 into the ventromedial hypothalamus modulates feeding, blood glucose levels, and hypothalamic POMC gene expression but not the HPA axis. Am. J. Physiol. Endocrinol. Metab. 298, E337-E345 (2010).
170. Deussing, J. M. et al. Urocortin 3 modulates social discrimination abilities via corticotropin-releasing hormone receptor type 2. J. Neurosci. 30, 9103-9116 (2010).
171. Lewis, K. et al. Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc. Natl Acad. Sci. USA 98, 7570-7575 (2001).
172. Merchenthaler, I., Vigh, S., Petrusz, P. & Schally, A. V. Immunocytochemical localization of corticotropin-releasing factor (CRF) in the rat brain. Am. J. Anat. 165, 385-396 (1982).
173. Reyes, T. M. et al. Urocortin II: a member of the corticotropin-releasing factor (CRF) neuropeptide family that is selectively bound by type 2 CRF receptors. Proc. Natl Acad. Sci. USA 98, 2843-2848 (2001).
174. Grammatopoulos, D. K., Randeva, H. S., Levine, M. A., Kanellopoulou, K. A. & Hillhouse, E. W. Rat cerebral cortex corticotropin-releasing hormone receptors: evidence for receptor coupling to multiple G-proteins. J. Neurochem. 76, 509-519 (2001).
175. Grammatopoulos, D. K. & Chrousos, G. P. Functional characteristics of CRH receptors and potential clinical applications of CRH-receptor antagonists. Trends Endocrinol. Metab. 13, 436-444 (2002).
176. Brar, B. K., Chen, A., Perrin, M. H. & Vale, W. Specificity and regulation of extracellularly regulated kinase1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2β by the CRF/urocortin family of peptides. Endocrinology 145, 1718-1729 (2004).
177. 2(a) receptors endogenously expressed in human retinoblastoma Y79 cells: passage-dependent regulation of functional receptors. J. Neurochem. 104, 926-936 (2008).
178. Markovic, D., Punn, A., Lehnert, H. & Grammatopoulos, D. K. Intracellular mechanisms regulating corticotropin-releasing hormone receptor 2β endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades. Mol. Endocrinol. 22, 689-706 (2008).
179. Erdtmann-Vourliotis, M., Mayer, P., Ammon, S., Riechert, U. & Hollt, V. Distribution of G-protein-coupled receptor kinase (GRK) isoforms 2, 3, 5 and 6 mRNA in the rat brain. Brain Res. Mol. Brain Res. 95, 129-137 (2001).
180. Gurevich, E. V., Benovic, J. L. & Gurevich, V. V. Arrestin2 and arrestin3 are differentially expressed in the rat brain during postnatal development. Neuroscience 109, 421-436 (2002).
181. Lemos, J. C. et al. Severe stress switches CRF action in the nucleus accumbens from appetitive to aversive. Nature 490, 402-406 (2012).
182. Joels, M. & Baram, T. Z. The neuro-symphony of stress. Nat. Rev. Neurosci. 10, 459-466 (2009).
183. Dautzenberg, F. M. & Hauger, R. L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol. Sci. 23, 71-77 (2002).
184. Perrin, M. H. & Vale, W. W. Corticotropin releasing factor receptors and their ligand family. Ann. NY Acad. Sci. 885, 312-328 (1999).
185. Lovenberg, T. W. et al. Cloning and characterization of a functionally distinct corticotropin-releasing factor receptor subtype from rat brain. Proc. Natl Acad. Sci. USA 92, 836-840 (1995).
186. Perrin, M. et al. Identification of a second corticotropin-releasing factor receptor gene and characterization of a cDNA expressed in heart. Proc. Natl Acad. Sci. USA 92, 2969-2973 (1995).
187. Stenzel, P. et al. Identification of a novel murine receptor for corticotropin-releasing hormone expressed in the heart. Mol. Endocrinol. 9, 637-645 (1995).
188. Vaughan, J. et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378, 287-292 (1995).
189. Behan, D. P. et al. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides. Front. Neuroendocrinol. 16, 362-382 (1995).
190. Seasholtz, A. F., Valverde, R. A. & Denver, R. J. Corticotropin-releasing hormone-binding protein: biochemistry and function from fishes to mammals. J. Endocrinol. 175, 89-97 (2002).
191. Slater, P. G., Cerda, C. A., Pereira, L. A., Andres, M. E. & Gysling, K. CRF binding protein facilitates the presence of CRF type 2α receptor on the cell surface. Proc. Natl Acad. Sci. USA 113, 4075-4080 (2016).
192. Hauger, R. L., Risbrough, V., Brauns, O. & Dautzenberg, F. M. Corticotropin releasing factor (CRF) receptor signaling in the central nervous system: new molecular targets. CNS Neurol. Disord. Drug Targets 5, 453-479 (2006).
193. Gutknecht, E. et al. Molecular mechanisms of corticotropin-releasing factor receptor-induced calcium signaling. Mol. Pharmacol. 75, 648-657 (2009).
194. Kelly, E., Bailey, C. P. & Henderson, G. Agonist-selective mechanisms of GPCR desensitization. Br. J. Pharmacol. 153, S379-S388 (2008).
195. Kohout, T. A. & Lefkowitz, R. J. Regulation of G protein-coupled receptor kinases and arrestins during receptor desensitization. Mol. Pharmacol. 63, 9-18 (2003).
196. Moore, C. A., Milano, S. K. & Benovic, J. L. Regulation of receptor trafficking by GRKs and arrestins. Annu. Rev. Physiol. 69, 451-482 (2007).
197. 2 adrenergic receptor requires both receptor phosphorylation and receptor activation. J. Biol. Chem. 280, 9528-9535 (2005).
198. Bender, J. et al. Corticotropin-releasing hormone receptor type 1 (CRHR1) clustering with MAGUKs is mediated via its C-terminal PDZ binding motif. PLoS ONE 10, e0136768 (2015).
199. Walther, C., Caetano, F. A., Dunn, H. A. & Ferguson, S. S. PDZK1/NHERF3 differentially regulates corticotropin-releasing factor receptor 1 and serotonin 2A receptor signaling and endocytosis. Cell. Signal. 27, 519-531 (2015).
200. Magalhaes, A. C., Dunn, H. & Ferguson, S. S. Regulation of GPCR activity, trafficking and localization by GPCR-interacting proteins. Br. J. Pharmacol. 165, 1717-1736 (2012).
201. Dunn, H. A. et al. PSD 95 regulates CRFR1 localization, trafficking and β arrestin2 recruitment. Cell. Signal. 28, 531-540 (2016).
202. Griebel, G. & Holsboer, F. Neuropeptide receptor ligands as drugs for psychiatric diseases: the end of the beginning? Nat. Rev. Drug Discov. 11, 462-478 (2012).
203. Young, E. A., Abelson, J. L. & Cameron, O. G. Effect of comorbid anxiety disorders on the hypothalamic-pituitary-adrenal axis response to a social stressor in major depression. Biol. Psychiatry 56, 113-120 (2004).
204. 1 receptor antagonist NBI 34041: preclinical and clinical data suggest safety and efficacy in attenuating elevated stress response. Neuropsychopharmacology 32, 1941-1949 (2007).
205. Zobel, A. W. et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J. Psychiatr. Res. 34, 171-181 (2000).
206. 1 receptor-antagonist R121919 improves sleep-EEG in patients with depression. J. Psychiatr. Res. 38, 129-136 (2004).
207. 1 antagonist) in the treatment of major depression. Am. J. Psychiatry 165, 617-620 (2008).
208. Kimura, M. et al. Conditional corticotropin-releasing hormone overexpression in the mouse forebrain enhances rapid eye movement sleep. Mol. Psychiatry 15, 154-165 (2010).
209. Holsboer, F. & Ising, M. Stress hormone regulation: biological role and translation into therapy. Annu. Rev. Psychol. 61, 81-109 (2010).
210. Valentino, R. J., Van Bockstaele, E. & Bangasser, D. Sex-specific cell signaling: the corticotropin-releasing factor receptor model. Trends Pharmacol. Sci. 34, 437-444 (2013).
211. Holmes, K. D., Babwah, A. V., Dale, L. B., Poulter, M. O. & Ferguson, S. S. Differential regulation of corticotropin releasing factor 1α receptor endocytosis and trafficking by β-arrestins and Rab GTPases. J. Neurochem. 96, 934-949 (2006).
212. 1 receptor phosphorylation and β-arrestin-2 recruitment: a mechanism regulating stress and anxiety responses. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R209-R222 (2007).
213. Keen-Rhinehart, E. et al. Continuous expression of corticotropin-releasing factor in the central nucleus of the amygdala emulates the dysregulation of the stress and reproductive axes. Mol. Psychiatry 14, 37-50 (2009).
214. Regev, L. et al. Prolonged and site-specific over-expression of corticotropin-releasing factor reveals differential roles for extended amygdala nuclei in emotional regulation. Mol. Psychiatry 16, 714-728 (2011).
215. Chen, Y. et al. Impairment of synaptic plasticity by the stress mediator CRH involves selective destruction of thin dendritic spines via RhoA signaling. Mol. Psychiatry 18, 485-496 (2013).
216. Andres, A. L. et al. NMDA receptor activation and calpain contribute to disruption of dendritic spines by the stress neuropeptide CRH. J. Neurosci. 33, 16945-16960 (2013).
217. Wang, X. D. et al. Forebrain CRHR1 deficiency attenuates chronic stress-induced cognitive deficits and dendritic remodeling. Neurobiol. Dis. 42, 300-310 (2011).
218. Ivy, A. S. et al. Hippocampal dysfunction and cognitive impairments provoked by chronic early-life stress involve excessive activation of CRH receptors. J. Neurosci. 30, 13005-13015 (2010).
219. Brewin, C. R., Kleiner, J. S., Vasterling, J. J. & Field, A. P. Memory for emotionally neutral information in posttraumatic stress disorder: a meta-analytic investigation. J. Abnorm Psychol. 116, 448-463 (2007).
220. 1 receptor antagonist SSR125543 prevents stress-induced cognitive deficit associated with hippocampal dysfunction: comparison with paroxetine and D cycloserine. Psychopharmacol. (Berl.) 228, 97-107 (2013).
221. Koenig, J. I., Walker, C. D., Romeo, R. D. & Lupien, S. J. Effects of stress across the lifespan. Stress 14, 475-480 (2011).
222. Sauvage, M. & Steckler, T. Detection of corticotropin-releasing hormone receptor 1 immunoreactivity in cholinergic, dopaminergic and noradrenergic neurons of the murine basal forebrain and brainstem nuclei - potential implication for arousal and attention. Neuroscience 104, 643-652 (2001).
223. Pollandt, S. et al. Cocaine withdrawal enhances long-term potentiation induced by corticotropin-releasing factor at central amygdala glutamatergic synapses via CRF, NMDA receptors and PKA. Eur. J. Neurosci. 24, 1733-1743 (2006).
224. Kash, T. L. & Winder, D. G. Neuropeptide Y and corticotropin-releasing factor bi-directionally modulate inhibitory synaptic transmission in the bed nucleus of the stria terminalis. Neuropharmacology 51, 1013-1022 (2006).
225. Lodge, D. J. & Grace, A. A. Acute and chronic corticotropin-releasing factor 1 receptor blockade inhibits cocaine-induced dopamine release: correlation with dopamine neuron activity. J. Pharmacol. Exp. Ther. 314, 201-206 (2005).
226. Wang, H. L., Wayner, M. J., Chai, C. Y. & Lee, E. H. Corticotrophin-releasing factor produces a long-lasting enhancement of synaptic efficacy in the hippocampus. Eur. J. Neurosci. 10, 3428-3437 (1998).
227. 1 modulates early-life stress-programmed cognitive deficits. J. Neurosci. 31, 13625-13634 (2011).
228. Zieba, B. et al. The behavioural and electrophysiological effects of CRF in rat frontal cortex. Neuropeptides 42, 513-523 (2008).